Key terms
About GLYC
GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GLYC news
Apr 05
8:46am ET
Largest borrow rate increases among liquid names
Mar 28
8:20am ET
Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), GlycoMimetics (GLYC)
Mar 27
9:25pm ET
Positive Outlook for GlycoMimetics: Buy Rating Affirmed Amid Anticipated Pivotal Trial Results and Strategic Growth Initiatives
Mar 27
12:35pm ET
Buy Recommendation for GlycoMimetics Based on Promising Upro Drug Prospects and Strong Pipeline
Mar 27
12:30pm ET
Analysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Perspective Therapeutics (CATX)
Mar 27
11:35am ET
Buy Rating on GlycoMimetics Backed by Strong Financials and Promising Phase 3 Trial of Uproleselan
Mar 27
7:15am ET
GlycoMimetics reports Q4 EPS (14c), consensus (15c)
Mar 25
8:00am ET
Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
Mar 01
9:32am ET
GlycoMimetics Provides Update with Investor Presentation
Feb 22
7:46am ET
Promising Outlook for GlycoMimetics’ Uproleselan in AML Treatment: A Buy Rating with Adjusted Price Target
Jan 26
11:25am ET
Biotech Alert: Searches spiking for these stocks today
No recent press releases are available for GLYC
GLYC Financials
Key terms
Ad Feedback
GLYC Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GLYC Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
